Loading quotes...
Forecast
| Buy |
7 |
| Hold |
1 |
| Sell |
0 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | 2023 | YoY |
|---|---|---|
| Revenue | 1.61m | - |
| Gross profit | -1.53m | 273.58% |
| Net profit | -56.99m | 60.40% |
| EBITDA | -48.29m | 168.67% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €3.9m |
Number of shares | 132.64m |
52-week high/low | €0.0355 - €0.0294 |
| Dividends | No |
Beta | 1.03 |
P/E ratio | -0.08 |
PEG ratio | 0.00 |
P/B ratio | -1.65 |
P/S ratio | 2.43 |
Company profile
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. In addition, the company is developing NK cell pipeline comprising GDA-301, GDA-401, GDA-501, and GDA-601 to treat hematologic malignancies and solid tumors. The company was founded in 1998 and is headquartered in Jerusalem, Israel.
| Name | Gamida Cell |
| CEO | Abigail L. Jenkins |
| Headquarters | Jerusalem,
Israel |
| Website | |
| Sector | Consumer Staples |
| Industry | Food Products |
| IPO | 26/10/2018 |
| Employees | 143 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | GMDA |
